Comparative Pharmacology
Head-to-head clinical analysis: CORTICOTROPIN versus COSYNTROPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTICOTROPIN versus COSYNTROPIN.
CORTICOTROPIN vs COSYNTROPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticotropin (ACTH) stimulates the adrenal cortex to release cortisol, corticosterone, aldosterone, and androgens via activation of melanocortin 2 receptor (MC2R) in the zona fasciculata and reticularis.
Synthetic adrenocorticotropic hormone (ACTH) analog that stimulates adrenal cortex to secrete cortisol, corticosterone, and androgens.
40-80 units IM or SC every 24-72 hours; dose adjusted based on response.
250 mcg to 2500 mcg intramuscularly or intravenously, with 250 mcg being the most commonly used dose for cosyntropin stimulation test; frequency as needed per test protocol.
None Documented
None Documented
15-30 minutes (intravenous); clinically, duration of action (via adrenal stimulation) exceeds half-life due to sustained cAMP-mediated effects.
Terminal elimination half-life is approximately 15 minutes; rapid clearance requires continuous infusion or frequent dosing for sustained effect.
Primarily metabolized in tissues via proteolysis; negligible renal excretion of intact hormone (<5%); urinary metabolites include small peptide fragments.
Primarily renal; >90% of dose excreted unchanged in urine; negligible biliary/fecal elimination.
Category C
Category C
Corticotropin
Corticotropin